Martinsried/Munich, April 4, 2008. On April 7, the biotech company MediGene AG (Frankfurt, Prime Standard: MDG) will hold an analyst and investor conference call which will be webcast on the internet. During this conference, MediGene will present details of the clinical phase II trial of the drug candidate EndoTAG®-1. The most important details will be published in a press release on April 7 in the morning.
